SX-682 Recruiting Phase 2 Trials for Stage IV Lung Cancer AJCC v8 / Metastatic Non-Small Cell Lung Cancer / Stage IIIC Lung Cancer AJCC v8 / Recurrent Non-Small Cell Lung Carcinoma Treatment

Indications	Status	Purpose	Phase
DBCOND0111249 (Stage IV Lung Cancer AJCC v8) DBCOND0043377 (Metastatic Non-Small Cell Lung Cancer) DBCOND0111248 (Stage IIIC Lung Cancer AJCC v8) DBCOND0035923 (Recurrent Non-Small Cell Lung Carcinoma)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT05570825	SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer	Pembrolizumab (DB09037) SX-682 (DB19210)